Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses a phase II study that examined the activity of alisertib monotherapy in patients with neuroendocrine prostate cancer.
Winald Gerritsen, MD, PhD
Advertisement
Articles by Winald Gerritsen, MD, PhD
Winald Gerritsen, MD, PhD, professor and medical oncologist, Radboud Medical Center, discusses some of the recent shortcomings seen with immunotherapy agents in the treatment of patients with castration-resistant prostate cancer.
Advertisement
Latest Updated Articles
Dr. Gerritsen on Shortcomings of Immunotherapy in Prostate CancerPublished: October 26th 2016 | Updated:
Dr. Gerritsen on a Study of Alisertib in Neuroendocrine Prostate CancerPublished: December 2nd 2016 | Updated:
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts BLA for Ivonescimab Plus Chemotherapy in EGFR-Mutant NSCLC After TKI Progression
2
FDA Grants Fast Track Designation to IBI3003 in Relapsed/Refractory Multiple Myeloma
3
Oncology Fellows Presents a New Drug Cheat Sheet for Fellows
4
Third NDA for Rivoceranib/Camrelizumab Is Resubmitted to FDA for Unresectable HCC
5